We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Vernalis | LSE:VER | London | Ordinary Share | GB00B3Y5L754 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.17 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
03/11/2016 00:05 | 12 to 15 months from now if the earlier announcement pans out.Getting FDA clearance for a new site and production quality won't be easy. I don't know why they didn't come to some arrangement with the administrator for the previous plant in Ireland. | fhmktg | |
02/11/2016 14:46 | fhmktg ...the trade at 11.48 and 11.49 look like a roll over...when are they going to inform us about the supply lines and if another producer has been found . | twodegrees | |
02/11/2016 13:43 | Interesting cluster of buys today! | fhmktg | |
02/11/2016 05:15 | Do you guys realize that not all drugs that get FDA approval go on to sell in a way that makes the parent company any lolly ? | buywell3 | |
14/10/2016 20:52 | fhmktg thank you...looks interesting with a pipeline of work on the go. | twodegrees | |
14/10/2016 00:05 | www.fiscalstandard.c | fhmktg | |
14/10/2016 00:01 | Just google Cantor Fitzgerald and Vernalis | fhmktg | |
13/10/2016 16:30 | fhmktg...do you have a link to the cantor target | twodegrees | |
13/10/2016 16:23 | not that is a bloomin good target...what do they know that they are not sharing with us... | twodegrees | |
13/10/2016 15:45 | Ah! It was Cantor Fitzgerald setting a target price of 101p. | fhmktg | |
13/10/2016 08:52 | Somebody is building their stake this morning! | fhmktg | |
12/10/2016 14:39 | fhmtg thanks for that...I was thinking that financial messages had changed codes or something.... let us hope that a new supplier is named soon. | twodegrees | |
12/10/2016 13:11 | oh, re-establishing, now that makes sense :) yes could do with more news on that | bountyhunter | |
11/10/2016 23:22 | Sorry for the spelling; I wouldn't have thought they would go ahead promoting the product to the market unless they had some candidates in line to provide reliable manufacture of the Product before their limited supply runs out.Maybe I'm missing something? | fhmktg | |
11/10/2016 20:50 | fhmktg I had followed that but what do you mean by confident about rare-establishing a supplier | twodegrees | |
11/10/2016 17:36 | See news release in May | fhmktg | |
11/10/2016 17:34 | The Irish supplier of the formulation for Moxatag has gone into administration. | fhmktg | |
11/10/2016 16:57 | fhmktg care to explain please...note we have hit another new low. | twodegrees | |
11/10/2016 16:40 | Must be confident about rare-establishing a supplier! | fhmktg | |
02/10/2016 12:17 | Review listed on the Vectura board lists Verona RPL554 as a potential new type of treatment for athsma and related conditions.This is from VER stable. | fhmktg | |
29/9/2016 15:07 | Another 'bolt on' product would come in handy. | fhmktg | |
29/9/2016 15:06 | The PowerPoint presentation gives a good detailed outline of Tuzistra and its market reaction and strategy.Good learning for the introduction of the next product for season 17/18. Keep the faith! | fhmktg | |
29/9/2016 14:51 | ok, the current situation regarding that is not entirely clear from today's RNS, I hope you're wrong as well as we would probably both benefit! | bountyhunter | |
29/9/2016 11:18 | How do you work that out from the following statements in today's RNS? -- "Focused US primary care sales force fully recruited, trained and deployed to the field -- US rights to Moxatag(R) , the only US approved once-a-day formulation of amoxicillin, acquired in October 2015, validating the Company's ability to expand its US commercial portfolio ...Re-launch Moxatag(R) in the US market through our focused US primary care sales force (H2 2016 calendar year) ...We will leverage this investment and our US commercial infrastructure to launch the once-a-day antibiotic, Moxatag(R) in the second half of 2016. ...Our cash position was bolstered following the recent equity raise to continue the promotional investment in Tuzistra(R) XR as well as launch Moxatag(R) and our additional products, CCP-07 and CCP-08 in the near term. We remain very excited about the growth potential of the business." There is still just over 3 months to go to the end of the H2 2016 calendar year with autumn/winter just starting. | bountyhunter |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions